Home
>
US Stocks
>
Alector Inc

Alector Inc (ALEC)

$6.83

-0.61

(-8.2%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Insights on Alector Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 14.44M → 16.54M (in $), with an average increase of 12.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -52.42M → -45.85M (in $), with an average increase of 14.3% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 44.0% return, outperforming this stock by 65.6%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 21.0% return, outperforming this stock by 100.2%

Performance

  • $6.67
    $7.41
    $6.83
    downward going graph

    2.34%

    Downside

    Day's Volatility :9.99%

    Upside

    7.83%

    downward going graph
  • $5.76
    $13.50
    $6.83
    downward going graph

    15.67%

    Downside

    52 Weeks Volatility :57.33%

    Upside

    49.41%

    downward going graph

Returns

PeriodAlector IncSector (Health Care)Index (Russel 2000)
3 Months
-17.11%
0.7%
-7.0%
6 Months
-24.95%
-7.9%
-6.5%
1 Year
-21.58%
-2.0%
-6.8%
3 Years
-79.24%
25.4%
24.7%

Highlights

Market Capitalization
620.1M
Book Value
$2.2
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.62
Wall Street Target Price
11.0
Profit Margin
-107.05%
Operating Margin TTM
-114.43%
Return On Assets TTM
-10.56%
Return On Equity TTM
-59.73%
Revenue TTM
125.7M
Revenue Per Share TTM
1.52
Quarterly Revenue Growth YOY
-32.4%
Gross Profit TTM
-76.8M
EBITDA
-138.3M
Diluted Eps TTM
-1.62
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.06
EPS Estimate Next Year
-2.42
EPS Estimate Current Quarter
-0.75
EPS Estimate Next Quarter
-0.82

Analyst Recommendation

Buy
    70%Buy
    23%Hold
    5%Sell
Based on 17 Wall street analysts offering stock ratings for Alector Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
4
4
4
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 61.05%

Current $6.83
Target $11.00

Company Financials

FY17Y/Y Change
Revenue
3.7M
↑ 797.84%
Net Income
-32.5M
↑ 114.96%
Net Profit Margin
-869.61%
↑ 2762.6%
FY18Y/Y Change
Revenue
27.7M
↑ 641.02%
Net Income
-52.2M
↑ 60.86%
Net Profit Margin
-188.78%
↑ 680.83%
FY19Y/Y Change
Revenue
21.2M
↓ 23.33%
Net Income
-105.4M
↑ 101.7%
Net Profit Margin
-496.65%
↓ 307.87%
FY20Y/Y Change
Revenue
21.1M
↓ 0.57%
Net Income
-190.2M
↑ 80.51%
Net Profit Margin
-901.64%
↓ 404.99%
FY21Y/Y Change
Revenue
207.1M
↑ 881.54%
Net Income
-36.3M
↓ 80.9%
Net Profit Margin
-17.54%
↑ 884.1%
FY22Y/Y Change
Revenue
133.6M
↓ 35.48%
Net Income
-133.3M
↑ 266.95%
Net Profit Margin
-99.77%
↓ 82.23%
Q4 FY21Q/Q Change
Revenue
14.0M
↓ 92.33%
Net Income
-55.6M
↓ 143.93%
Net Profit Margin
-397.37%
↓ 466.77%
Q1 FY22Q/Q Change
Revenue
24.5M
↑ 74.89%
Net Income
-44.6M
↓ 19.77%
Net Profit Margin
-182.3%
↑ 215.07%
Q2 FY22Q/Q Change
Revenue
79.9M
↑ 226.27%
Net Income
9.9M
↓ 122.15%
Net Profit Margin
12.38%
↑ 194.68%
Q3 FY22Q/Q Change
Revenue
14.9M
↓ 81.4%
Net Income
-46.1M
↓ 566.94%
Net Profit Margin
-310.72%
↓ 323.1%
Q4 FY22Q/Q Change
Revenue
14.4M
↓ 2.77%
Net Income
-52.4M
↑ 13.61%
Net Profit Margin
-363.07%
↓ 52.35%
Q1 FY23Q/Q Change
Revenue
16.5M
↑ 14.61%
Net Income
-45.9M
↓ 12.53%
Net Profit Margin
-277.1%
↑ 85.97%
FY17Y/Y Change
Total Assets
236.1M
↑ 336.25%
Total Liabilities
288.1M
↑ 264.59%
FY18Y/Y Change
Total Assets
308.4M
↑ 30.63%
Total Liabilities
405.8M
↑ 40.84%
FY19Y/Y Change
Total Assets
421.9M
↑ 36.83%
Total Liabilities
227.2M
↓ 44.01%
FY20Y/Y Change
Total Assets
488.3M
↑ 15.72%
Total Liabilities
220.7M
↓ 2.84%
FY21Y/Y Change
Total Assets
814.7M
↑ 66.85%
Total Liabilities
513.9M
↑ 132.84%
FY22Y/Y Change
Total Assets
787.6M
↓ 3.32%
Total Liabilities
573.2M
↑ 11.53%
Q4 FY21Q/Q Change
Total Assets
814.7M
↓ 4.63%
Total Liabilities
513.9M
↓ 0.85%
Q1 FY22Q/Q Change
Total Assets
954.5M
↑ 17.16%
Total Liabilities
686.9M
↑ 33.66%
Q2 FY22Q/Q Change
Total Assets
889.7M
↓ 6.79%
Total Liabilities
601.2M
↓ 12.49%
Q3 FY22Q/Q Change
Total Assets
837.0M
↓ 5.92%
Total Liabilities
583.9M
↓ 2.86%
Q4 FY22Q/Q Change
Total Assets
787.6M
↓ 5.9%
Total Liabilities
573.2M
↓ 1.84%
Q1 FY23Q/Q Change
Total Assets
748.3M
↓ 4.99%
Total Liabilities
565.3M
↓ 1.37%
FY17Y/Y Change
Operating Cash Flow
-17.8M
↑ 36.77%
Investing Cash Flow
-801.0K
↓ 64.4%
Financing Cash Flow
-15.0K
↓ 80.52%
FY18Y/Y Change
Operating Cash Flow
127.5M
↓ 817.26%
Investing Cash Flow
-224.1M
↑ 27879.9%
Financing Cash Flow
131.1M
↓ 874406.67%
FY19Y/Y Change
Operating Cash Flow
-99.3M
↓ 177.91%
Investing Cash Flow
-48.9M
↓ 78.19%
Financing Cash Flow
172.4M
↑ 31.42%
FY20Y/Y Change
Operating Cash Flow
-166.7M
↑ 67.9%
Investing Cash Flow
-105.1M
↑ 114.94%
Financing Cash Flow
232.1M
↑ 34.67%
FY21Y/Y Change
Operating Cash Flow
298.6M
↓ 279.06%
Investing Cash Flow
-49.7M
↓ 52.72%
Financing Cash Flow
30.3M
↓ 86.95%
Q4 FY21Q/Q Change
Operating Cash Flow
-49.3M
↓ 111.07%
Investing Cash Flow
-146.8M
↑ 112.52%
Financing Cash Flow
8.6M
↓ 41.72%
Q1 FY22Q/Q Change
Operating Cash Flow
135.1M
↓ 374.21%
Investing Cash Flow
-12.1M
↓ 91.75%
Financing Cash Flow
2.5M
↓ 71.25%
Q2 FY22Q/Q Change
Operating Cash Flow
-57.4M
↓ 142.52%
Investing Cash Flow
-225.8M
↑ 1765.35%
Financing Cash Flow
906.0K
↓ 63.51%
Q3 FY22Q/Q Change
Operating Cash Flow
-49.1M
↓ 14.6%
Investing Cash Flow
60.5M
↓ 126.8%
Financing Cash Flow
489.0K
↓ 46.03%
Q1 FY23Q/Q Change
Operating Cash Flow
-48.5M
↓ 0.77%
Investing Cash Flow
88.7M
-
Financing Cash Flow
1.1M
↑ 69.65%

Technicals Summary

Sell

Neutral

Buy

Alector Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alector Inc
Alector Inc
6.89%
-24.95%
-21.58%
-79.24%
-62.06%
Moderna, Inc.
Moderna, Inc.
-2.19%
-29.52%
-8.32%
114.67%
590.97%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.43%
-4.6%
15.93%
18.38%
134.28%
Seagen, Inc.
Seagen, Inc.
-2.63%
59.03%
43.99%
21.05%
216.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.48%
0.7%
19.84%
13.84%
116.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alector Inc
Alector Inc
15.47
NA
NA
-3.06
-0.6
-0.11
0.0
2.2
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alector Inc
Alector Inc
Buy
$620.1M
-62.06%
15.47
-107.05%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
590.97%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
134.28%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
216.49%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
116.25%
26.18
35.4%

Institutional Holdings

  • BlackRock Inc

    8.84%

  • Vanguard Group Inc

    7.68%

  • FMR Inc

    5.65%

  • Federated Hermes Inc

    5.48%

  • EcoR1 Capital, LLC

    4.87%

  • State Street Corporation

    4.28%

Company Information

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain's immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company's immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer's disease. This scientific approach is also the basis for the Company's immuno-oncology programs.

Organization
Alector Inc
Employees
273
CEO
Dr. Tillman Ulf Gerngross Ph.D.
Industry
Biotechnology

Discover More

FAQs